Skip to content

The Study for the Cervical Cancer Screening and Treatment Algorithms Study Using HPV Testing in Africa

The Study for the Cervical Cancer Screening and Treatment Algorithms Study Using HPV Testing in Africa

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04794660
Acronym
CESTA
Enrollment
1500
Registered
2021-03-12
Start date
2019-10-01
Completion date
2025-10-01
Last updated
2024-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HPV Infection

Keywords

VIA triage, HIV serostatus

Brief summary

The main objectives of CESTA are (1) to compare the efficacy of two cervical cancer screening algorithms: HPV test followed by visual inspection with acetic acid (VIA) and treatment (HPV + VIA + treat) and HPV test followed by immediate treatment (HPV + treat). The study will be conducted to address its objectives in women living with HIV (from now on called HIV positive women); and 2) To evaluate the performance of other techniques for primary screening and as triage for HPV positives WLHIV. 1,500 women living with HIV WLHIV will be recruited from HIV care clinics, also called antiretrovirals (ARV) clinics in South Africa. After giving informed consent, women will be screened with HPV testing and those that have a HPV positive test will be randomized at a 4:1 ratio into HPV + VIA + treat (Arm 1) and HPV + treat (Arm 2). Women in Arm 1 will receive VIA and only positive for VIA will be treated. In Arm 2, all HPV positive women will be treated. Women that are eligible for ablative treatment will be randomized into treatment with TA or cryotherapy in both arms. Others will be referred to colposcopy. After VIA in Arm 1 or before treatment in Arm 2, the nurses will collect 2-4 biopsies on all HPV positive women. The biopsies will be used as gold standard for disease detection. Treated women will be called by telephone after 1 week and 1 month to assess side-effects and satisfaction with the procedures. Cervical samples from women will be tested with HPV DNA test and HPV mRNA test to evaluate different screening tests for WLHIV. All women with a positive HPV test (treated or not) will be called back after 1 year for a follow-up visit. At this visit, women will be screened with HPV testing and VIA and 2-4 colposcopy-directed biopsies will be taken from all HPV positive women. Women with remaining/recurrent CIN2+ disease will receive appropriate management.

Interventions

DIAGNOSTIC_TESTHPV DNA Test

Screening for HPV using a HPV DNA test

DIAGNOSTIC_TESTVIA triage test

VIA is a technique in which cervical neoplastic lesions are visually diagnosed after application of 3-5% acetic acid without using any magnification device. After application of 3 - 5% acetic acid, using the naked eye, the cervix is examined for the presence of an aceto-white lesion located in the transformation zone. The results are classified as either positive or negative, inadequate or suspicion of cancer

PROCEDURETreatment by ablative treatment

Cryotherapy or Thermal Ablation are performed on the cervix.

PROCEDUREColposcopy

Colposcopy visit are offered to women with non visible squamous columnar junction or ineligible for ablative treatment.

Sponsors

World Health Organization
CollaboratorOTHER
University of KwaZulu
CollaboratorOTHER
Cheikh Anta Diop University, Senegal
CollaboratorOTHER
Walter Sisulu University
CollaboratorOTHER
International Agency for Research on Cancer
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
DOUBLE (Subject, Caregiver)

Masking description

Care providers and participants are masked to the intervention ahead of the intervention. However, the strategy delivery is not blinded.

Eligibility

Sex/Gender
FEMALE
Age
25 Years to 54 Years
Healthy volunteers
Yes

Inclusion criteria

* Willing to disclose HIV status * HIV negative women aged 30-54 years; HIV positive women aged 25-54 years * Mentally competent to give informed consent * Physically able to have a pelvic exam

Exclusion criteria

* Women reporting no previous sexual activity * History of cervical cancer * Treatment for cervical precancer in the last six months * Hysterectomy * Pregnancy * Serious pre-existing medical conditions (e.g. history of bleeding disorders, serious physical or mental disease)

Design outcomes

Primary

MeasureTime frame
Percentage of women treated with high grade lesions in both armsup top 1 month
Percentage of women treated with low grade lesions in both armsup to 1 month

Secondary

MeasureTime frameDescription
Persistence of HPV infection and lesions at one yearup to 14 monthsall HPV positive women at screening will be asked to come back at one year to be tested for HPV. HPV positive women at one year will be refered to colposcopy and biopsies will be taken

Countries

Senegal, South Africa

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026